India, March 27 -- Shares of Dermata Therapeutics, Inc. (DRMA) gains 26% on Thursday morning after the biotechnology company announced positive topline results from the company's first pivotal Phase 3 trial of Xyngari for the treatment of moderate-to-severe acne.
DRMA is currently trading at $1.6999, up $0.3499 or 26.1100%, on a volume of 64 million shares, above average volume of 343 thousand, on the Nasdaq. The stock opened its trading at $2.2002 after closing Wednesday at $1.3500. The stock has traded between $1.0000 and $6.6600 in the past 52-week period.
Xyngari also appeared to be safe and well tolerated by patients with minimal treatment related adverse events and no serious adverse events attributed to treatment.
googletag.cmd.pu...